This final episode in KDIGO’s four-part IgAN series focuses on the challenges and opportunities of implementing the updated KDIGO IgAN Guideline in clinical practice.

The conversation examines a shifting treatment paradigm that emphasizes earlier intervention and simultaneous, multi-targeted therapy, while addressing persistent barriers to guideline adoption, including gaps in disease awareness, diagnostic precision, and risk stratification.

Drawing on insights from recent clinical trials, the discussion also explores how emerging evidence is shaping therapeutic decision-making, highlights priority areas for future IgAN research, and considers what continued innovation may mean for improving long-term patient outcomes.

The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, US), and features Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US). Previous episodes in the series feature KDIGO IgAN Guideline Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, US), Shikha Wadwani, MD (Cedars Sinai, US), Andrew Lazar, MD (University Hospitals of Cleveland, US), and Gaia Coppock, MD (University of Pennsylvania Medicine, US).

This podcast series was supported by Travere.

This third episode in KDIGO’s four-part IgAN series explores how to apply KDIGO guidance in real-world IgAN care through two illustrative patient cases. Building on earlier episodes in the series, the discussion highlights dynamic risk assessment, treatment selection, and monitoring strategies, along with practical decisions about RAS inhibitors versus DEARAs, TRF-budesonide versus systemic glucocorticoids, and the use of SGLT2 inhibitors. The episode also addresses complex scenarios, including rapidly progressive glomerulonephritis, nephrotic syndrome, acute kidney injury, pediatric IgAN, pregnancy, and treatment considerations in resource-limited settings.

The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, US), and features Gaia Coppock, MD (University of Pennsylvania Medicine, US), and Andrew Lazar, MD (University Hospitals of Cleveland, US). Previous episodes in the series feature KDIGO IgAN Guideine Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, US), and Shikha Wadwani, MD (Cedars-Sinai, US). The fourth and final episode will be released in December 2025 and will focus on the challenges of implementing evidence-based guidance, emerging therapies, and key research needs.

This podcast series was supported by Travere.

In the final episode of KDIGO’s three-part Conversations in Nephrology series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), speaks with Titilayo Ilori, MD (Boston University, United States), and kidney health advocate Joshua Albright (United States) about how APOL1 genetic testing can shape the future of kidney care. Their conversation brings together clinical expertise and lived experience to examine why early detection matters, how to overcome barriers to equitable testing, and what it will take to turn awareness into meaningful action for patients and communities.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/

This podcast was supported by Vertex Pharmaceuticals.

In this second installment of KDIGO’s three-part podcast series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), welcomes Barry Freedman, MD (Wake Forest University School of Medicine, United States) for a practical discussion on patient management.

They examine how APOL1 risk variants influence progression, review current therapeutic approaches, and explore emerging targeted treatments designed to improve care and outcomes for affected individuals.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/

This podcast was supported by Vertex Pharmaceuticals.

This is the first episode of a three-part KDIGO Conversations in Nephrology series on APOL1 kidney disease. Host Kirk Campbell, MD (University of Pennsylvania, United States), speaks with Bessie Young, MD (University of Washington, United States) about the discovery, burden, and biology of APOL1 kidney disease. Their discussion explores how APOL1 variants contribute to increased kidney disease risk in people of African ancestry, recent findings on protective variants, and ongoing research toward targeted therapies.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/

This podcast was supported by Vertex Pharmaceuticals.

This second episode in KDIGO’s four-part IgAN series addresses the treatment revolution in IgAN. Join Dana Rizk, MD (University of Alabama at Birmingham, US), and Shikha Wadhwani, MD (University of Texas Medical Branch, US) in understanding how disease pathophysiology is fueling a wave of new therapies that go beyond traditional supportive care.

Key topics include what's changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.

The first episode in this series (Episode #24) features KDIGO IgAN Guideline Co-Chair, Brad Rovin, MD (University of Ohio Medicine, US). Future episodes (Episode #29 and Episode #30) feature Shikha Wadwani, MD (Cedars Sinai, US), Andrew Lazar, MD (University Hospitals of Cleveland, US), Gaia Coppock, MD (University of Pennsylvania Medicine, US), and Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US), and cover lessons from IgAN Case Files, and challenges and strategies to implementing KDIGO IgAN Guideline recommendations.

This podcast was supported by Travere.

This is the first episode in KDIGO's four-part series on the KDIGO 2025 IgAN/IgAV Guideline. Join Dana Rizk, MD (University of Alabama at Birmingham, United States), and Brad Rovin, MD (Ohio State University, United States), Co-Chair of the 2025 KDIGO IgAN Guideline, for a deep dive into the latest updates in patient care. Their conversation explores the key takeaways from the new guideline, the critical role of kidney biopsies in diagnosis and prognosis, the use of the IgAN prediction tool for risk assessment, and the updated thresholds and treatment goals aimed at improving outcomes.

Future episodes (Episode #25, Episode #29, and Episode #30) feature Shikha Wadwani, MD (Cedars Sinai, US), Andrew Lazar, MD (University Hospitals of Cleveland, US), Gaia Coppock, MD (University of Pennsylvania Medicine, US), and Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US), and cover the treatment revolution in IgAN, lessons from IgAN Case Files, and challenges and strategies to implementing KDIGO IgAN Guideline recommendations.

This podcast was supported by Travere.

What does life with a rare kidney disease really look like?

Marianne Silkjaer Nielsen (Founder of CompCure, Denmark) offers a powerful voice for patients and caregivers. She reflects on the long diagnostic journey, the challenges of managing rare kidney disease, and the need for better awareness, advocacy, and international registries to improve outcomes.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.